Regulatory News has published 1 story about Electra Therapeutics on 22 September 2026, sourced to the primary record — the regulator’s decision, the company’s filing or its own announcement. This page is generated from that coverage. Last updated 22 September 2026.
This page is generated from Regulatory News’ editorial coverage of Electra Therapeutics. It is not an advertisement.
On the record
- Company
- Electra Therapeutics, Inc. (Nasdaq: ETRA)
- Headquarters
- South San Francisco, California
- Founded
- October 2018, incorporated in Delaware as a subsidiary of Star Therapeutics
- Regulator
- U.S. Food and Drug Administration and European Medicines Agency (ipsoprubart holds FDA Fast Track, FDA Breakthrough Therapy and EMA PRIME designations)
Each line is taken from the most recent story of ours that states it.
Products in our coverage
Our coverage
